rHuEPO Dose Inversely Correlated with the Number of Circulating CD34+ Cells in Maintenance Hemodialysis Patients

Publisher： Karger

E-ISSN： 1660-2110|108|1|c41-c46

ISSN： 1660-2110

Source： Nephron Clin Pract, Vol.108, Iss.1, 2007-12, pp. : c41-c46

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 104-107

Karger

Access to resources Recommend Favorite

Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia

By  

Oncology Research and Treatment, Vol. 28, Iss. 4, 2005-10 ,pp. : 216-221

Karger

Access to resources Recommend Favorite

Prevention of Anemia in Patients with Solid Tumors Receiving Platinum-Based Chemotherapy by Recombinant Human Erythropoietin (rHuEpo): A Prospective, Open Label, Randomized Trial by the Hellenic Cooperative Oncology Group

By  

Oncology, Vol. 64, Iss. 2, 2003-02 ,pp. : 102-110

Karger

Access to resources Recommend Favorite

MDS-Patienten profitieren anhaltend von der Behandlung mit r-HuEPO und G-CSF

By  

Transfusion Medicine and Hemotherapy, Vol. 25, Iss. 2-3, 1998-06 ,pp. : 188-188

Karger

Access to resources Recommend Favorite

Circulating CD34++ progenitor cells and growth factors in patients treated with PCI for acute myocardial infarction or stable angina pectoris

By Grøøgaard Haakon K.   Solheim Svein   Landsverk Kirsti S.   Seljeflot Ingebjøørg   Hoffmann Pavel   Arnesen Harald   Ilebekk Arnfinn  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 71, Iss. 4, 2011-07 ,pp. : 322-329

Informa Healthcare

Access to resources Recommend Favorite